Skip to content

Kelly E Dunn

3 papers in the library · 22 citations · publishing 2011-2025

Papers

Sort Most recent Most cited

Combining mindfulness intervention and open-label placebo treatment for chronic pain: a protocol for a feasibility study.

Pilot and Feasibility Studies August 20, 2025 Chung Jung Mun, Estrella Contreras, Yushu Xiao et al.

Mindfulness-based interventions, such as mindfulness-based stress reduction (MBSR), are efficacious mind-body treatments for chronic pain, though their modest effect sizes suggest room for improvement. Notably, recent studies indicate that mindfulness meditation does not engage the endogenous opioid system, which plays an important role in analgesia. Therefore, exploring the combination of a...

DOI: 10.1186/s40814-025-01692-8 (opens in new tab) Full text (opens in new tab) Mindfulness Chronic pain Mind–body intervention Open-label placebo

Clinical Trial Design Challenges and Opportunities for Emerging Treatments for Opioid Use Disorder: A Review.

JAMA Psychiatry 2023 Brian D Kiluk, Bethea A Kleykamp, Sandra D Comer et al. 22 citations

Novel treatments for opioid use disorder (OUD) are needed to address both the ongoing opioid epidemic and long-standing barriers to existing OUD treatments that target the endogenous μ-opioid receptor (MOR) system. The goal of this review is to highlight unique clinical trial design considerations for the study of emerging treatments for OUD that address targets beyond the MOR system. In...

A survey study to characterize use of Spice products (synthetic cannabinoids).

Drug and Alcohol Dependence August 10, 2011 Ryan Vandrey, Kelly E Dunn, Jeannie A Fry et al.

Background: Synthetic cannabinoids are a rapidly emerging class of abused drugs. Synthetic cannabinoids are typically sold as "herbal blends" or "incense," commonly referred to as Spice products. No controlled human experiments have been conducted on the effects of Spice products or the synthetic cannabinoids they often contain. Methods: An internet-based survey study was conducted with adults...

DOI: 10.1016/j.drugalcdep.2011.07.011 (opens in new tab) Full text (opens in new tab) Humans Substance-related disorders Cannabinoids Data collection +4